drug
Rybelsus
Marketedupdated 5mo agoby Novo Nordisk Inc
Approvedcommunity read0 votes
🐶 often sniffed alongside
top 8- drugOzempic121 co-mentions · 73 sources
- drugWegovy121 co-mentions · 73 sources
- drugWegovy Pill94 co-mentions · 72 sources
- tagApproval88 co-mentions · 44 sources
- drugsemaglutide72 co-mentions · 72 sources
- tagRecall29 co-mentions · 27 sources
- tagSmall Molecule17 co-mentions · 17 sources
- companyNovo Nordisk Inc11 co-mentions · 4 sources
all catalysts(0)
nothing on the calendar yet
Trials studying Rybelsus
- phase1A Research Study Investigating How Adults With Overweight or Obesity, With or Without Type 2 Diabetes, Tolerate Switching to a New Treatment (Zenagamtide) From Their Current Semaglutide Medication
- —Real-World Patient and Physician Experience With Semaglutide Across Six Emerging Markets
- phase4Long Term Comparative Effectiveness of Once Weekly Semaglutide Versus Standard of Care in a Real World Adult US Population With Type 2 Diabetes - a Randomized Pragmatic Trial
- phase3A Research Study to See How Well CagriSema Helps People With Excess Body Weight Lose Weight
- phase1A Research Study Looking Into How a High Dose of s.c. Semaglutide Works With Emptying of the Stomach in People With Excess Body Weight
- phase3A Research Study Investigating How Well the Medicine Zenagamtide Helps People With Excess Body Weight Lose Weight Compared to Semaglutide
- phase3A Clinical Study Comparing Semaglutide Injection and Wegovy® for Weight Management in Obese Subjects
- phase2A Research Study to See if Kidney Damage in People With Chronic Kidney Disease and Type 2 Diabetes Living With Overweight or Obesity Can be Reduced by CagriSema Compared to Semaglutide, Cagrilintide and Placebo
News(10)
- Kailera, Hengrui’s GLP-1/GIP candidate delivers weight, menstrual benefits to women with PMOSKailera Therapeutics and Hengrui Pharma’s weekly injection showed benefits beyond weight loss in a mid-stage trial, leading to more regular menstrual cycles in patients with polyendocrine metabolic…biospace · 2d ago
- Fresenius Kabi manufacturing plant hit with FDA warning letter after adverse eventsPatients had adverse events after receiving a Fresenius Kabi medicine that experienced manufacturing deviations.biospace · 3d ago
- Sanofi pays Dupixent partner Regeneron $1B upfront for 4 early-stage assets to ignite R&DSanofi is paying Regeneron $1 billion upfront to collaborate on four early-stage immunology programs, teeing the longstanding partners up to try to replicate Dupixent’s success.fiercebiotech · 3d ago
- Superior weight loss, blood sugar control propel Lilly’s amylin-GIP/GLP-1 combo into Phase 3EloraTZP—a combination of an amylin asset and Eli Lilly’s approved obesity drug Zepbound—made a clean sweep of the primary and secondary endpoints in a mid-stage trial of adults with obesity and ty…biospace · 4d ago
- Lilly builds commercial case for GLP-1 products over Novo with indirect analysesEli Lilly’s weight loss pill Foundayo has had a “slower-than-hoped” launch, according to BMO Capital Markets, which contended that the indirect comparison data—despite falling short of definitive p…biospace · 4d ago
- Lilly raises diabetes weight-loss bar with amylin-Zepbound comboEli Lilly announced its amylin-Zepbound combination eloraTZP resulted in 23.3% weight loss in adults with type 2 diabetes and obesity or overweight, topping its own triple-G drug candidate retatrut…fiercebiotech · 4d ago
- Novo adds long-term obesity differentiation in up to $2.6B Hengrui dealInvestors looking for more transformative business development at Novo will have to wait, but a new partnership with China’s Hengrui Pharma adds a new weekly oral option to the Danish pharma’s earl…biospace · 5d ago
- Roche drops muscle-sparing obesity antibody after flunked interim analysisRoche has slammed the brakes on an obesity antibody after the candidate showed little hope of hitting its endpoints in a phase 2 study.fiercebiotech · 6d ago
- FDA slams GLP-1 compounder over risk of contaminating drugs ‘with filth’FDA inspectors found evidence that the compounding pharmacy was making versions of Eli Lilly’s tirzepatide and Novo’s semaglutide “regularly or in inordinate amounts” at a site with “insanitary con…biospace · 10d ago
- Novo’s workforce reduction climbs to 13,000 to fuel R&D workNovo CEO Maziar Mike Doustdar disclosed an additional 4,000 staff departures, which a spokesperson told BioSpace are linked to attrition and other measures.biospace · 12d ago
Data sources
last refreshed 2h ago
Found something off?
comments(0)
5-min edit window · permanent after that